| | | |  | Join STAT's Angus Chen and Damian Garde for a virtual discussion tomorrow with industry experts on the most prominent work presented at ASH 2022 and a look at what's coming in hematology in the year ahead. Sign up here. | | | | By Matthew Herper Ruby Wallau for STAT New data offers the first evidence of an effective individualized cancer vaccine based on mRNA, the technology used in the Covid shots. Read More | | By Adam Feuerstein Adobe Hopes that the Mirati lung cancer drug might reach a large swath of patients — and grow into a commercial blockbuster — have dimmed. Read More | | By Angus Chen Adobe Researchers had hoped that a protein called GPRC5D might offer a new way to get the immune system to hunt and destroy multiple myeloma cells. Read More | | Sponsored Insight by Hologic US cervical cancer screening rates dropped 36% in 2020 & have yet to rebound to pre-pandemic rates Cervical cancer screening rates have seen a significant drop since 2020 and haven't returned to pre-pandemic rates, according to a JAMA Oncology study. SEER data also show a significant increase in cervical cancer incidence from 2012-2019 in women ages 15-39 of all races/ethnicities, with the highest increase among Hispanic women. Gaps in preventive screenings inevitably lead to later-stage diagnoses and more severe health outcomes. Learn how Hologic is invested in improving access to cervical screenings. | | By Bob Herman Adobe For cancer patients who must make frequent trips for treatments like radiation and chemotherapy, the cost of daily parking fees adds up. Read More | | By Angus Chen Ruby Wallau for STAT The process, which Novartis calls the T-charge platform, cuts the standard 10-day CAR-T cell manufacturing time to less than two days. Read More | | By Ed Silverman Drew Angerer/Getty Images Experts presented "a lack of internally consistent, objective, science-based standards for the evenhanded evaluation of data," the judge wrote Read More | | By Adam Feuerstein CDC About one-third of patients with advanced leukemia experienced remissions in two new clinical trials of genetically targeted drugs. Read More | | By Angus Chen Adobe “This debunks a myth that we’ve been perpetuating forever,” hematologist Mikkael Sekeres said of the new study presented at the ASH meeting. Read More | | By Adam Feuerstein NIAID/NIH An experimental immunotherapy from Affimed has started to demonstrate long-lasting remissions for patients with advanced Hodgkin lymphoma. Read More | |
No comments